Proton beam therapy is an advanced form of external radiotherapy that uses high-energy proton beams instead of photon x-ray beams or electrons. Carefully measured doses of protons are delivered to the precise area needing treatment, using the latest IBA ProteusONE technology. This ensures that the delivery of proton beam therapy is highly accurate and prevents the risk of radiation reaching surrounding healthy tissue.
Radiotherapy is used to kill and destroy cancer cells. It utilises radiation in the form of high-energy x-rays, known as photons, to kill and damage the cancerous cells and prevent their growth and reproduction. It can be used as a non-surgical option to treat cancer, and it can also be used to shrink a tumour or in combination with other treatments.
The Rutherford Cancer Centres and Elekta are bringing the next generation of personalised adaptive radiotherapy technology to oncology centres across the UK, with the new MR-linac Elekta Unity now available at the Rutherford Cancer Centre North West in Liverpool.
Consultant Clinical Oncologist
Dr Jason Lester is a senior Consultant Clinical Oncologist based in South Wales. He trained and qualified in United Medical and Dental Schools of Guy’s & St Thomas’s in 1993. He completed his general medical training in London and the South East of England before moving to Wales in 1997. He joined Velindre Cancer Centre in 1997 and completed his Clinical Oncology training in 2003.
Dr Lester was appointed as a consultant Oncologist in 2003, specialising in the management of lung (non-small cell, small cell, mesothelioma) and urological (prostate, kidney, bladder) cancers. His NHS practice is based in South East Wales, with clinics in The Royal Gwent Hospital Newport, University Hospital Llandough and Cardiff.
He is currently Chairman of the Rutherford Cancer Centre Local Medical Advisory Committee for Wales. He is also the Clinical Lead for the All Wales Prostate Cancer Brachytherapy Service and Director of Stepping Stones, the Wales-based lung cancer charity.
Dr Lester participates in a large number of clinical trials in both lung and urological cancer sites, and has published extensively in these fields. He is the lead investigator in the I-START trial, (dose escalated radiotherapy) and the SKOPOS trial, a vaccine trial in malignant pleural mesothelioma. He is responsible for prescribing and supervising the administration of radiotherapy, radioisotope treatment, cytotoxic chemotherapy and hormone therapy.
Find out more by visiting Dr Jason Lester's website: www.lester-oncology.org
* Within the website, links to external sites and resources may be provided by third parties. Links to such sites are provided purely for your information only. It is the responsibility of the third party organisation to ensure any content on their websites comply with all relevant laws and regulations. Such links should not be interpreted as approval by us of those linked websites or information you may obtain from them. We have no control over the contents of those sites or resources. Our full Website terms of use can be found here.
This consultant has received training from the Rutherford Cancer Centres in the delivery of proton beam therapy. The programme, Proton Therapy Clinical Education, in conjunction with The Perelman School of Medicine at the University of Pennsylvania and IBA, the leading proton beam therapy solutions manufacturer, involves oncologists gaining practical experience in Penn’s Roberts Proton Therapy Center – one of the world’s leading centres of proton therapy research and expertise.
If you'd like to speak to us about any of the treatments we offer please don’t hesitate to get in touch. Call us on 0800 210 0402 or
© Copyright Rutherford Health Plc 2017 - 2022
All rights Reserved